Login to Your Account

'Acadia' Think It Really Works? After Two Fails, Phase III Win

By Randy Osborne
Staff Writer

Wednesday, November 28, 2012
Two strikes – and investor suspense – led up to a home run for Acadia Pharmaceuticals Inc., which tweaked the designs of previous, failed Phase III trials and thereby met all endpoints in the latest one with pimavanserin in Parkinson's disease psychosis (PDP).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription